Last Updated on October 17, 2024 by The Health Master
Dr Reddy”s Laboratories on Wednesday said the US health regulator has issued a Form 483 with three observations after inspecting its manufacturing facility in Middleburg, New York.
The audit of the company”s active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed by the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a regulatory filing.
“We have been issued a Form 483 with 3 (three) observations. We will address them comprehensively within the stipulated timeline. Currently, we do not have any sales from this plant,” it added.
As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related acts.
Shares of the company on Wednesday ended 1.15 per cent up at Rs 4,498.65 apiece on the BSE.
Also read:
World’s most expensive drug, costs ₹18 crore per dose
NATCO gets USFDA nod for Breast Cancer treatment drug
Kite gets USFDA nod for drug to treat Follicular Lymphoma
Shilpa Medicare gets USFDA tentative nod for drug for Arthritis
Aleor Dermaceuticals gets USFDA nod for Testosterone Gel
Unichem gets USFDA nod for Guanfacine Tablets
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
